Abstract
Essential hypertension is a major factor for myocardial infarction, heart failure and kidney failure. Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport and vasodilatation directly or indirectly with other hormones and humoral factors, such as reactive oxygen species and the renin-angiotensin system. Dopamine receptors are classified into five subtypes based on their structure and pharmacology. Among those dopamine receptor subtypes, D1 receptor is the most important one, during conditions of moderate sodium intake, more than 50% of renal sodium excretion is regulated by D1-like receptors. Decreased renal dopamine production and/or impaired D1 receptor function have been reported in hypertension. Disruption of D1 receptor results in hypertension. In this paper, we review the mechanisms by which hypertension develops when D1 receptor function is perturbed. We also discuss possible new approaches developing anti-hypertensive medicine by increasing renal dopamine production, enhancing D1 receptor function, or modifying its interactions with other blood pressure-regulating systems.
Keywords: Essential hypertension, D1 dopamine receptor, G protein-coupled receptor kinase type 4, protein phosphotase 2A, endocytosis, desensitization, sodium excretion, vasorelaxation
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: A New Approach for Treatment of Hypertension: Modifying D1 Dopamine Receptor Function
Volume: 4 Issue: 4
Author(s): Chunyu Zeng, Robin A. Felder and Pedro A. Jose
Affiliation:
Keywords: Essential hypertension, D1 dopamine receptor, G protein-coupled receptor kinase type 4, protein phosphotase 2A, endocytosis, desensitization, sodium excretion, vasorelaxation
Abstract: Essential hypertension is a major factor for myocardial infarction, heart failure and kidney failure. Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport and vasodilatation directly or indirectly with other hormones and humoral factors, such as reactive oxygen species and the renin-angiotensin system. Dopamine receptors are classified into five subtypes based on their structure and pharmacology. Among those dopamine receptor subtypes, D1 receptor is the most important one, during conditions of moderate sodium intake, more than 50% of renal sodium excretion is regulated by D1-like receptors. Decreased renal dopamine production and/or impaired D1 receptor function have been reported in hypertension. Disruption of D1 receptor results in hypertension. In this paper, we review the mechanisms by which hypertension develops when D1 receptor function is perturbed. We also discuss possible new approaches developing anti-hypertensive medicine by increasing renal dopamine production, enhancing D1 receptor function, or modifying its interactions with other blood pressure-regulating systems.
Export Options
About this article
Cite this article as:
Zeng Chunyu, Felder A. Robin and Jose A. Pedro, A New Approach for Treatment of Hypertension: Modifying D1 Dopamine Receptor Function, Cardiovascular & Hematological Agents in Medicinal Chemistry 2006; 4 (4) . https://dx.doi.org/10.2174/187152506778520727
DOI https://dx.doi.org/10.2174/187152506778520727 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy AT1 Receptor Antagonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology The Application of X-ray, NMR, and Molecular Modeling in the Design of MMP Inhibitors
Current Topics in Medicinal Chemistry GLP - 1 Analogs: Newer Molecules, Newer Uses
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets Natriuretic Peptides as the Basis of Peptide Drug Discovery for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Pharmacological and Clinical Applications of Natriuretic Peptides: Accepted Knowledges or Changing Views?
Current Pharmaceutical Analysis The In Vitro and In Vivo Inhibitory Effect of Dehydroaltenusin: A Specific Inhibitor of Mammalian DNA Polymerase α
Current Bioactive Compounds Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Specific Therapy Based on the Genotype and Cellular Mechanism in Inherited Cardiac Arrhythmias. Long QT Syndrome and Brugada Syndrome
Current Pharmaceutical Design Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions
Current Pharmaceutical Design Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
Current Drug Targets The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine